All In Biotech

Drug Trial Radar · NCT05606913

A Study of IBI362 in Participants With Type 2 Diabetes

Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)

Last checked: Nov 19, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 731 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

731

Actual

Start

Jan 6, 2023

Primary completion

Jan 26, 2024

Study completion Apr 9, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • dulaglutideDrug

    Dulaglutide administered subcutaneously (SC) once a week.

  • IBI362Drug

    IBI362 administered subcutaneously (SC) once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c change from baseline at week 28Time frame: Baseline, 28 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.